Amarin (AMRN) to Release Earnings on Wednesday

Amarin (NASDAQ:AMRN) will likely be announcing its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $43.7710 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:00 AM ET.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($1.27) by $1.28. The company had revenue of $49.22 million for the quarter, compared to analysts’ expectations of $50.62 million. Amarin had a negative return on equity of 5.46% and a negative net margin of 18.16%. On average, analysts expect Amarin to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Amarin Trading Down 0.8%

NASDAQ:AMRN opened at $14.51 on Wednesday. The stock has a market cap of $301.81 million, a P/E ratio of -161.22 and a beta of 0.81. The stock’s 50-day moving average is $14.84 and its 200-day moving average is $15.56. Amarin has a 1-year low of $9.44 and a 1-year high of $20.90.

Analyst Upgrades and Downgrades

AMRN has been the topic of several research reports. Zacks Research upgraded Amarin from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a report on Monday. Finally, Wall Street Zen lowered Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $12.00.

Hedge Funds Weigh In On Amarin

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jump Financial LLC lifted its stake in shares of Amarin by 38.7% in the fourth quarter. Jump Financial LLC now owns 26,900 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 7,500 shares during the period. Jane Street Group LLC lifted its stake in shares of Amarin by 90.6% in the fourth quarter. Jane Street Group LLC now owns 32,832 shares of the biopharmaceutical company’s stock worth $458,000 after acquiring an additional 15,608 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Amarin by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 2,008 shares during the period. Sei Investments Co. lifted its stake in shares of Amarin by 4.7% in the third quarter. Sei Investments Co. now owns 29,212 shares of the biopharmaceutical company’s stock worth $478,000 after acquiring an additional 1,299 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Amarin by 534.2% in the third quarter. JPMorgan Chase & Co. now owns 21,754 shares of the biopharmaceutical company’s stock worth $356,000 after acquiring an additional 18,324 shares during the period. 22.25% of the stock is owned by institutional investors and hedge funds.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.